Use of EDG receptor binding agents in cancer

Details for Australian Patent Application No. 2007237378 (hide)

Owner Novartis AG

Inventors Wood, Jeanette Marjorie; Lassota, Peter T.; Brinkmann, Volker; Baumruker, Thomas; La Montagne, Kenneth Richard; Mechtcheriakova, Diana

Agent Davies Collison Cave

Pub. Number AU-B-2007237378

Parent 2003240655

Filing date 5 December 2007

Wipo publication date 3 January 2008

Acceptance publication date 28 April 2011

International Classifications

A61K 45/00 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

A61K 31/135 (2006.01) - having aromatic rings, e.g. methadone

A61K 31/137 (2006.01) - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine

A61K 31/381 (2006.01) - having five-membered rings

A61K 31/661 (2006.01) - Phosphorus acids or esters thereof not having PC bonds, e.g. fosfosal, dichlorvos, malathion

A61P 9/00 (2006.01) Drugs for disorders of the cardiovascular system

A61P 35/00 (2006.01) Antineoplastic agents

A61P 35/04 (2006.01) Antineoplastic agents

A61P 43/00 (2006.01) Drugs for specific purposes, not provided for in groups

Event Publications

20 December 2007 Complete Application Filed

3 January 2008 Application Open to Public Inspection

  Published as AU-B-2007237378

28 April 2011 Application Accepted

  Published as AU-B-2007237378

25 August 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007237379-Sugar and lipid metabolism regulators in plants IV

2007237377-System and method for scheduling an event over a network